Coronary Thrombolysis
Related Experiment Video
Updated: Oct 2, 2026
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
1McMaster University Medical Centre, Hamilton, Ontario, Canada.
Insights
Thrombolytic therapy for acute myocardial infarction shows benefits, but questions remain regarding optimal use, routine angiography, and primary angioplasty comparisons. Further research is needed for definitive answers on risk-benefit and cost-effectiveness.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Thrombolytic therapy is a cornerstone treatment for acute myocardial infarction (AMI).
- Existing randomized trials have established general benefits and risks of thrombolysis.
- Several aspects of thrombolytic therapy and its alternatives require further investigation.
Purpose of the Study:
- To address unresolved questions regarding thrombolytic therapy for AMI.
- To evaluate the comparative efficacy and cost-effectiveness of different treatment strategies.
- To discuss the role of routine angiography in patients receiving thrombolysis.
Main Methods:
- Review and synthesis of data from randomized clinical trials.
- Analysis of findings from the GUSTO trial comparing rt-PA and SK.
- Discussion of current clinical guidelines and expert opinions.
Main Results:
- The GUSTO trial demonstrated superior efficacy of rt-PA over SK for AMI.
- The precise benefit size, risk-benefit ratios, and cost-effectiveness of rt-PA require further clarification.
- The utility of routine coronary angiography post-thrombolysis remains debated due to limited evidence.
Conclusions:
- While rt-PA is more effective than SK, its exact benefits and cost-effectiveness need more study.
- Routine angiography after thrombolysis is not currently recommended, but may be considered by some clinicians.
- Primary angioplasty may offer benefits over thrombolysis, but further trials are needed to confirm outcomes and cost-effectiveness.
Abstract:
Randomized trials have demonstrated the overall benefits and risks of thrombolytic therapy for acute myocardial infarction, and have evaluated adjunctive drug therapies, adjunctive and primary angioplasty, various approaches to the timing of thrombolysis, and post-thrombolysis management. Three questions, which remain unanswered, are addressed in this Point-Counterpoint Series. The GUSTO trial provides convincing evidence of the greater efficacy of rt-PA by comparison to SK, but the size of the benefit is uncertain, as are the risk benefit ratios and cost-effectiveness in various patient subgroups. The issues of whether or not routine angiography is appropriate for patients who have received coronary thrombolysis remains unresolved. For the present, clinical guidelines are likely to advise against routine angiography, while many cardiologists, concerned about the shortcomings of available studies, may wish to undertake coronary angiography in many of their patients, even though definitive proof of its benefit is lacking. Although randomized clinical trials suggest a benefit of primary angioplasty over thrombolytic therapy, further studies are required to clarify the comparative benefits in terms of clinically important outcomes and cost-effectiveness.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies